Meeting
2022 ASCO Annual Meeting
Penpulimab plus anlotinib in patients with recurrent or metastatic head and neck squamous cell carcinoma after the failure of first-line platinum-based chemotherapy: A single-arm, multicenter, phase 2 study.
Authors
Changgong Zhang
Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
Changgong Zhang , Liying Gao , Youxin Tian , Chunmei Bai , Jianhua Chen , Jun Wang , Xingya Li , Yan Sun , Haichuan Su , Zhigang Liu , Yuankai Shi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04203719
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6027)
DOI
10.1200/JCO.2022.40.16_suppl.6027
Abstract #
6027
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
First Author: Zhiwei Chang
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu
Poster
2023 ASCO Annual Meeting
A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.
First Author: Taiji Koyama